

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **SUPPLEMENTAL ANNOUNCEMENT VERY SUBSTANTIAL DISPOSAL AND CONNECTED TRANSACTION: DISPOSAL OF THE TARGET SHARES IN THE TARGET COMPANIES**

References are made to the announcements of Yestar Healthcare Holdings Company Limited (the “**Company**”) dated 30 December 2022 and 3 January 2023 in relation to the Disposal and the Default (as defined below) (collectively, the “**Announcements**”). Unless otherwise defined therein, capitalised terms and expressions used herein shall have the same meanings as those defined in the Announcements. The Board would like to provide the following supplemental information in relation to the Disposal and the Default (as defined below).

Under the indenture governing the New Senior Notes, the Company is due to redeem 5% of the original principal amount of the New Senior Notes by 30 December 2022. The Company did not redeem any of the New Senior Notes as at the date of this announcement. In addition, the interest on the New Senior Notes became due and payable on 30 December 2022. (the “**Default**”). As the Default have occurred and are currently continuing, the Company is prohibited by the terms of the indenture from consummating the asset sale. As the result, the noteholders of the New Senior Notes have the right under the indenture to immediately accelerate repayment of the entire principal amount of the New Senior Notes, together with any premium and accrued and unpaid interest. As at the date of this announcement, the Company is maintaining communication with the noteholders of the New Senior Notes.

As disclosed in the announcement of the Company dated 30 December 2022, the net proceeds of the Disposal of approximately RMB430.0 million will be used to settle the outstanding liabilities of the Remaining Group, and reduce its indebtedness, improve the liquidity and the overall financial position of the Remaining Group, which are critical to stay competitive locally and internationally and generate long-term growth to shareholders. Therefore, the net proceeds from the Disposal will serve as a source of funding for settlement of part of the outstanding liabilities, including the New Senior Notes, which will be also beneficial to the noteholders of the New Senior Notes.

Further announcements will be made by the Company in relation to the progress of any significant business updates as and when appropriate.

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Liao Changxiang**  
*CEO and executive Director*

22 March 2023

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.*